TORONTO (MedPage Today) -- Adding the fourth-generation fluoroquinolone moxifloxacin (Avelox) to standard tuberculosis therapy may allow treatment times to be shortened, an international study suggests.
Novel TB Regimen May Allow Shorter TreatmentCourtesy MedPage Today Infectious Disease Thu, 04/02/2009 - 16:30
TORONTO (MedPage Today) -- Adding the fourth-generation fluoroquinolone moxifloxacin (Avelox) to standard tuberculosis therapy may allow treatment times to be shortened, an international study suggests. More related items'Totally' Resistant TB Surfaces in India
Shorter Combo TB Regimen Matches Standard Therapy...
TB Reaches Record Low in U.S.
|
Popular by tags WeekMonth |
Post new comment